CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for F-Star Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

F-Star Therapeutics Inc
Eddeva B920, Babraham Research Campus
Phone: +44 1223497400p:+44 1223497400 CAMBRIDGE, MA  CB22 3AT  United Kingdom Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 3/8/2023.
This company ceased filing statements with the SEC on 3/20/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing immunotherapies to transform the lives of patients with cancer. The Company's FS118 is the lead product candidate, which is in Phase II trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing FS222, FS120 and SB 11285 in Phase I clinical trials in patients with advanced cancers. FS222 is focused on patients with tumors that express low levels of PD-L1 and is a tetravalent, bispecific natural antibody (mAb2) bispecific antibody that is designed to target both the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. FS120 is focused to improve checkpoint inhibitor and chemotherapy outcomes and is a mAb2 bispecific antibody that is designed to bind to and stimulate OX40 and CD137. Its product candidate SB 11285 is focused on improving checkpoint inhibition outcomes as an immunotherapeutic compound for the treatment of selected cancers.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202212/31/2021YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board NessanBermingham 49 5/1/2019 5/1/2019
President, Chief Executive Officer, Director EliotForster 55 11/20/2020 10/1/2018
Chief Financial Officer, Treasurer, Secretary DarleneDeptula-Hicks 64 1/1/2021 5/1/2019
6 additional Officers and Directors records available in full report.

Business Names
Business Name
F-star Therapeutics Limited
FSTX
SBP Securities Corporation
SBPH

General Information
Number of Employees: 84 (As of 3/1/2022)
Outstanding Shares: 21,981,919 (As of 9/30/2022)
Shareholders: 155
Stock Exchange: NASD
Federal Tax Id: 522386345
Fax Number: (302) 655-5049
Email Address: info@springbankpharm.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, April 8, 2024